TuHURA Biosciences (HURA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

HURA · Stock Price

USD 2.40-1.53 (-38.93%)

Market Cap: $147.7M

Historical price data

Market Cap: $147.7MFounded: 2019HQ: Tampa, United States

Sector Ranking#22 in RNA Therapeutics (non-mRNA)#57 in Cell & Gene Therapy

Overview

TuHURA Biosciences is a Phase 3 immuno-oncology company with a mission to develop therapeutics that overcome primary and acquired resistance to cancer immunotherapies. Founded in 2019, the company has aggressively built a diversified pipeline through internal R&D and the strategic 2025 acquisition of Kineta, Inc., which added the clinical-stage VISTA inhibitor TBS-2025. TuHURA's strategy focuses on accelerating development via regulatory pathways for unmet needs in both solid tumors (e.g., Merkel cell carcinoma) and hematological cancers (e.g., AML), aiming to broaden the efficacy of existing treatments like checkpoint inhibitors.

OncologyImmuno-oncology

Technology Platform

Three distinct platforms: 1) Immune Fx (IFx) innate immune agonist using bacterial flagellin/TLR5 signaling; 2) a VISTA-inhibiting monoclonal antibody (TBS-2025); and 3) a Delta Opioid Receptor (DOR) platform for creating bispecific antibody-peptide conjugates (APCs) and antibody-drug conjugates (ADCs) targeting MDSCs.

Funding History

2

Total raised:$90M

Series B$65MBristol Myers SquibbFeb 15, 2023

Series A$25MMorningside VenturesJun 15, 2021

Opportunities

The primary opportunity lies in overcoming resistance to checkpoint inhibitors, a multi-billion dollar market gap.

Success in Merkel cell carcinoma via accelerated approval could provide a rapid path to market and validate the platform for expansion.

The entry into AML with TBS-2025 targets a wide-open field with no approved immunotherapies, representing a massive untapped market.

Risk Factors

High clinical risk associated with the novel IFx-2.0 Phase 3 trial and earlier-stage assets.

Significant financial risk due to pre-revenue status and the need to fund costly late-stage trials, likely leading to shareholder dilution.

Execution risk in integrating the Kineta acquisition and advancing multiple platforms simultaneously with limited resources.

Competitive Landscape

Faces competition in innate immune agonists from TLR-focused firms and intratumoral therapy developers, in VISTA inhibition from several biotechs, and in myeloid-targeting from companies pursuing CD47 and chemokine receptors. TuHURA's differentiation stems from its unique TLR5 mechanism, focused AML strategy for VISTA, and novel DOR-targeting approach for MDSCs.